Dr. Nancy Reid
Dyslipidemia has been on the rise and is an influencing factor behind adulthood cardiovascular disease; thus, it qualifies for pharmacologic intervention. This problem has prompted the American Academy of Pediatrics to establish a clinical report on modality to prevent, screen, diagnose, and treat dyslipidemia in pediatric patients.
While the use of statins (3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors) is recommended for pediatric dyslipidemia treatment in pediatric familial hypercholesterolemia, the efficacy and extent of variations in dose exposure and profile responses result in adverse events and treatment failure within pediatric patients. However, concerns regarding the long-term efficacy and safety of statins used with pediatric patients are yet to be established. We will evaluate the safety and efficacy of the use or disuse of statins for the treatment of pediatric dyslipidemia based on research from the International Pharmaceutical Abstracts, review articles, and the MEDLINEⓇ database.
Alnaqeeb, Amer B.
"To Statin or Not to Statin in a High-Risk Pediatric Patient Population,"
Lynchburg Journal of Medical Science: Vol. 3
, Article 6.
Available at: https://digitalshowcase.lynchburg.edu/dmscjournal/vol3/iss3/6
Available when accessing via a campus IP address or logged in with a University of Lynchburg email address.
Off-campus users can also use 'Off-campus Download' button above for access.